Alpha memo: resveratrol exercise context boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Re-scope the alpha to acknowledge that the 'context-dependent split' may equally reflect dose, duration, training modality, or endpoint axes and call out population as one of several candidate moderators, not the only one.
2. Verify and correct the DOI for Receipt 1 (the current DOI ends in a generic '111111' placeholder pattern).
3. Replace the absolute claim that resveratrol 'split rather than augment' cardiovascular gains with language that explicitly states the exercise-led change (the visible '45' endpoint) and characterizes the resveratrol interaction direction strictly per the abstract wording ('blunting' of training-induced improvements), without introducing effect sizes or specific endpoints not visible in the supplied excerpt.
4. Add a one-line description of which cardiovascular parameter was reported in Receipt 2 (the abstract identifies MAP as the baseline vascular measure and VO2max as the aerobic capacity measure) and explicitly note that the supplied excerpt truncates before the resveratrol-comparison statistic is given.

Major issues

• Receipt 2 cardiovascular endpoint specificity: the abstract truncates at 'Exercise training led to a 45' without completing the sentence in the supplied excerpt, yet the memo's abstract asserts resveratrol 'split rather than augment the cardiovascular gains of training.' The 45 figure appears to be an exercise-training effect size (likely MAP reduction ~4.5 mmHg or a % change), and the abstract does not contain sufficient information to confirm the blunt claim as stated. The memo should explicitly mark which endpoint is implicated and acknowledge that the direction/size of the resveratrol interaction is not fully visible in the supplied excerpt.

Minor issues

• Title says 'context boundary' but the 'boundary' is confounded by simultaneous mismatches in dose (250 mg vs 500/1000 mg), duration (8 vs 12 weeks), baseline health (healthy vs functional limitations), and endpoint family (cardiovascular vs physical function/mitochondrial), so the memo's attribution of the split to 'population/context' alone overstates what the contrast can localize.
• Receipt 1 (2021) is currently cited as a 2020-pub entry via DOI '10.1016/j.exger.2020.111111'; the placeholder DOI style suggests a fabricated placeholder rather than a verified identifier — this should be checked and corrected against the actual Exp Gerontol DOI.

Reviewer note

This is a concise two-receipt alpha memo that frames a defensible population/context contrast between a 2021 functional-limitations pilot RCT and a 2013 healthy-aged-men cardiovascular RCT. The synthesis is tight: it identifies the shared anchor (resveratrol + exercise), the differing populations/endpoints, and a falsifier path. However, the abstract overclaims by stating resveratrol 'split rather than augment' cardiovascular gains without the supplied excerpt ever showing that comparison statistic — the abstract truncates mid-sentence after reporting only the exercise-alone effect. The memo's caveats partially mitigate this but should be tightened into the headline claim. The DOI for Receipt 1 looks like a placeholder ('111111' suffix) and should be verified. The 'context boundary' frame is reasonable but currently conflates population with dose, duration, and endpoint family; the revision should localize the moderator hypothesis more carefully. Source grounding is reasonable given reference-only bundles; bundle entries match the prose citations by author-year and topic. Borderline revise: salvageable with bounded edits to the headline claim, moderator localization, and DOI check.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis